Tags

Type your tag names separated by a space and hit enter

Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients.
Liver Transpl 2003; 9(7):737-40LT

Abstract

Although living donor liver transplantation (LDLT) is a successful procedure for most recipients, outcomes in patients who undergo transplantation as United Network for Organ Sharing status 2A are marginal. There are no published data on living donor liver transplant recipient outcomes relative to Model for End-Stage Liver Disease (MELD) scores. Such information could be useful in living donor liver transplant recipient selection. We retrospectively analyzed all non-fulminant hepatic failure, right hepatic lobe, adult-to-adult living donor liver transplant recipients at our center between August 1997 and March 2002. We calculated MELD scores at the time of LDLT and correlated scores with 1-year patient and graft survival and hospital days during the 90-day post-LDLT period. There were 62 recipients with greater than 6 months of follow-up: 38 men, 24 women; mean age, 47.9 years; 42 white, 1 black, 17 Hispanic, and 2 Asian patients. Twenty-nine patients had hepatitis C virus infection; 4 patients, hepatitis C virus infection and alcoholic liver disease; 4 patients, alcoholic liver disease; 4 patients, cryptogenic cirrhosis; 13 patients, primary sclerosing cholangitis; 5 patients, autoimmune hepatitis; and 3 patients, primary biliary cirrhosis. Mean and median MELD scores were 15.2 and 13, respectively (range, 6 to 40). One-year patient and graft survival were 59 of 62 patients (95%) and 52 of 62 patients (84%), respectively. There was no statistically significant difference between median MELD scores of dead versus living patients (15 v 13; P =.15) or patients who underwent retransplantation versus those who did not (16.5 v 13; P =.30). Mean and median hospital days in the 90-day post-LDLT period were 23.7 and 16.0 days, respectively. Living donor liver transplant recipients with a MELD score of 18 or greater had significantly more hospital days compared with recipients with a MELD score less than 18 (35.2 v 19.8 days; P =.01). In conclusion, MELD scores did not predict post-LDLT patient or graft survival at 1 year. However, higher MELD scores (> or =18) were associated with more hospital days during the 3-month post-LDLT period.

Authors+Show Affiliations

Division of Gastroenterology/Hepatology, University of Colorado Health Sciences Center, Denver 80262, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

12827562

Citation

Hayashi, Paul H., et al. "Model for End-Stage Liver Disease Score Does Not Predict Patient or Graft Survival in Living Donor Liver Transplant Recipients." Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, vol. 9, no. 7, 2003, pp. 737-40.
Hayashi PH, Forman L, Steinberg T, et al. Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients. Liver Transpl. 2003;9(7):737-40.
Hayashi, P. H., Forman, L., Steinberg, T., Bak, T., Wachs, M., Kugelmas, M., ... Trotter, J. F. (2003). Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients. Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 9(7), pp. 737-40.
Hayashi PH, et al. Model for End-Stage Liver Disease Score Does Not Predict Patient or Graft Survival in Living Donor Liver Transplant Recipients. Liver Transpl. 2003;9(7):737-40. PubMed PMID: 12827562.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Model for End-Stage Liver Disease score does not predict patient or graft survival in living donor liver transplant recipients. AU - Hayashi,Paul H, AU - Forman,Lisa, AU - Steinberg,Tracy, AU - Bak,Thomas, AU - Wachs,Michael, AU - Kugelmas,Marcelo, AU - Everson,Gregory T, AU - Kam,Igal, AU - Trotter,James F, PY - 2003/6/27/pubmed PY - 2003/9/17/medline PY - 2003/6/27/entrez SP - 737 EP - 40 JF - Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society JO - Liver Transpl. VL - 9 IS - 7 N2 - Although living donor liver transplantation (LDLT) is a successful procedure for most recipients, outcomes in patients who undergo transplantation as United Network for Organ Sharing status 2A are marginal. There are no published data on living donor liver transplant recipient outcomes relative to Model for End-Stage Liver Disease (MELD) scores. Such information could be useful in living donor liver transplant recipient selection. We retrospectively analyzed all non-fulminant hepatic failure, right hepatic lobe, adult-to-adult living donor liver transplant recipients at our center between August 1997 and March 2002. We calculated MELD scores at the time of LDLT and correlated scores with 1-year patient and graft survival and hospital days during the 90-day post-LDLT period. There were 62 recipients with greater than 6 months of follow-up: 38 men, 24 women; mean age, 47.9 years; 42 white, 1 black, 17 Hispanic, and 2 Asian patients. Twenty-nine patients had hepatitis C virus infection; 4 patients, hepatitis C virus infection and alcoholic liver disease; 4 patients, alcoholic liver disease; 4 patients, cryptogenic cirrhosis; 13 patients, primary sclerosing cholangitis; 5 patients, autoimmune hepatitis; and 3 patients, primary biliary cirrhosis. Mean and median MELD scores were 15.2 and 13, respectively (range, 6 to 40). One-year patient and graft survival were 59 of 62 patients (95%) and 52 of 62 patients (84%), respectively. There was no statistically significant difference between median MELD scores of dead versus living patients (15 v 13; P =.15) or patients who underwent retransplantation versus those who did not (16.5 v 13; P =.30). Mean and median hospital days in the 90-day post-LDLT period were 23.7 and 16.0 days, respectively. Living donor liver transplant recipients with a MELD score of 18 or greater had significantly more hospital days compared with recipients with a MELD score less than 18 (35.2 v 19.8 days; P =.01). In conclusion, MELD scores did not predict post-LDLT patient or graft survival at 1 year. However, higher MELD scores (> or =18) were associated with more hospital days during the 3-month post-LDLT period. SN - 1527-6465 UR - https://www.unboundmedicine.com/medline/citation/12827562/Model_for_End_Stage_Liver_Disease_score_does_not_predict_patient_or_graft_survival_in_living_donor_liver_transplant_recipients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1527646503002089 DB - PRIME DP - Unbound Medicine ER -